Einat Almon - Protalix Biotherapeutics Sr. VP of Product Devel.
PLX Stock | USD 1.20 0.02 1.69% |
SVP
Dr. Einat Brill Almon, Ph.D., is Senior Vice President Product Development of Protalix BioTherapeutics Inc. She joined Protalix Ltd. in December 2004, originally as a Senior Director and later as a Vice President and then Senior Vice President, Product Development, and became our Senior Vice President, Product Development in 2006. Dr. Almon has many years of experience in the management of life science projects and companies, including biotechnology and agrobiotech, with direct experience in clinical, device and scientific software development, as well as a strong background and work experience in intellectual property. Prior to joining Protalix Ltd., from 2001 to 2004, she served as Director of RD and IP of Medgenics Medical Ltd., a company that developed an autologous platform for tissuebased protein drug delivery. Medgenics Medical, based in Israel, is a whollyowned subsidiary of Aevi Genomic Medicine, Inc. . Dr. Almon has trained as a biotechnology patent agent at leading IP firms in Israel since 2006.
Age | 57 |
Tenure | 18 years |
Professional Marks | Ph.D |
Address | Science Park, Karmiel, Israel, 2161401 |
Phone | 972 4 902 8100 |
Web | https://www.protalix.com |
Protalix Biotherapeutics Management Efficiency
The company has Return on Asset of 0.0933 % which means that on every $100 spent on assets, it made $0.0933 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.725 %, implying that it generated $0.725 on every 100 dollars invested. Protalix Biotherapeutics' management efficiency ratios could be used to measure how well Protalix Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Protalix Biotherapeutics' Return On Tangible Assets are fairly stable compared to the past year. Return On Capital Employed is likely to rise to 0.28 in 2024, whereas Return On Equity is likely to drop 0.24 in 2024. At this time, Protalix Biotherapeutics' Other Current Assets are fairly stable compared to the past year. Return On Tangible Assets is likely to rise to 0.10 in 2024, whereas Total Assets are likely to drop slightly above 51 M in 2024.Similar Executives
Found 3 records | SVP Age | ||
Teresa Compton | Akebia Ther | N/A | |
Mary MPH | Aldeyra | 57 | |
Nicole Hadas | Akebia Ther | 51 |
Management Performance
Return On Equity | 0.73 | ||||
Return On Asset | 0.0933 |
Protalix Biotherapeutics Leadership Team
Elected by the shareholders, the Protalix Biotherapeutics' board of directors comprises two types of representatives: Protalix Biotherapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Protalix. The board's role is to monitor Protalix Biotherapeutics' management team and ensure that shareholders' interests are well served. Protalix Biotherapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Protalix Biotherapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Roger Kornberg, Independent Director | ||
Eyal MBA, CFO, VP | ||
Yoseph Shaaltiel, Founder and Executive VP of RandD | ||
Shlomo Yanai, Chairman of the Board | ||
Yaron Naos, Senior Vice President - Operations | ||
Amos BarShalev, Independent Director | ||
Tzvi Palash, COO | ||
Yael Fellous, Vice Resources | ||
Dror Bashan, President CEO | ||
Aharon Schwartz, Independent Director | ||
Zeev Bronfeld, Independent Interim Chairman of the Board | ||
Einat Almon, Sr. VP of Product Devel. | ||
Yossi Maimon, CFO, Vice President Treasurer, Secretary | ||
David Granot, Independent Director | ||
Marcy Nanus, Investor Contact | ||
Moshe Manor, CEO and President and Director | ||
Yodfat Buchris, Independent Director |
Protalix Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Protalix Biotherapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.73 | ||||
Return On Asset | 0.0933 | ||||
Profit Margin | 0.13 % | ||||
Operating Margin | (0.54) % | ||||
Current Valuation | 67.92 M | ||||
Shares Outstanding | 73.05 M | ||||
Shares Owned By Insiders | 9.76 % | ||||
Shares Owned By Institutions | 13.90 % | ||||
Number Of Shares Shorted | 6.46 M | ||||
Price To Earning | (1.23) X |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Protalix Biotherapeutics using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Protalix Biotherapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Protalix Stock please use our How to Invest in Protalix Biotherapeutics guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Complementary Tools for Protalix Stock analysis
When running Protalix Biotherapeutics' price analysis, check to measure Protalix Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protalix Biotherapeutics is operating at the current time. Most of Protalix Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Protalix Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protalix Biotherapeutics' price. Additionally, you may evaluate how the addition of Protalix Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation |
Is Protalix Biotherapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Protalix Biotherapeutics. If investors know Protalix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Protalix Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.39) | Earnings Share 0.09 | Revenue Per Share 0.97 | Quarterly Revenue Growth 0.217 | Return On Assets 0.0933 |
The market value of Protalix Biotherapeutics is measured differently than its book value, which is the value of Protalix that is recorded on the company's balance sheet. Investors also form their own opinion of Protalix Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Protalix Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Protalix Biotherapeutics' market value can be influenced by many factors that don't directly affect Protalix Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Protalix Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Protalix Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Protalix Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.